Welcome back to another episode of The BioHub, we were thrilled to welcome on Nolan Townsend, CEO of Lexeo Therapeutics.Nolan has been at the helm of Lexeo since January 2020, leading a clinical-stage genetic medicine company aiming to transform treatment for genetically-defined cardiovascular diseases and APOE4-associated Alzheimer’s disease.
Under his leadership, Lexeo has built a pipeline of therapies rooted in breakthrough science, partnered with prominent academic institutions like Weill Cornell Medicine, and raised significant capital to support its mission. Before Lexeo, Nolan spent more than a decade at Pfizer, where he was President of Pfizer Rare Disease for North America, and also President for its International Rare Disease operations — overseeing strategy, cross-functional teams, and large operating budgets.
